Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure

Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Diseases Cardiovascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Essen

Essen, North Rhine-Westphalia, 45147, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients presenting with symptoms of heart failure to the West-German Heart and Vascular Center according to the definition of the ESC 2016.

Patients fulfilling criteria for the diagnosis of HFrEF
Patients fulfilling criteria for the diagnosis of HFpEF
Patients fulfilling criteria for the diagnosis of HFmrEF
Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.

Exclusion criteria

Age < 18 years
Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016
Denial to participate

Treatment and study plan

MIF ELISA

Diagnostic Test

Blood sample

Primary outcomes

180 days mortality

Time frame: 180 days

Sponsors and collaborators

Lead sponsor

University Hospital, Essen

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2020
Study completion: 2020
First posted: Jul 28, 2017
Registry last updated: Nov 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed